Delving into the Latest Updates on Ipsen Pharma Biotech SAS with Synapse

Overview

Tags

Other Diseases

Neoplasms

Endocrinology and Metabolic Disease

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Synthetic peptide	1

Top 5 Target	Count

SSTR(Somatostatin receptor)	1

The purpose of this study is to further characterize the clinical efficacy and safety of Lanreotide Autogel as a monotherapy for tumor control in Chinese participants in routine clinical practice to supplement the bridging study and support the clinical trial application. The medical records were reviewed approximately 48 weeks after the start of treatment with Lanreotide Autogel.

Start Date10 Feb 2022

Sponsor / Collaborator

Ipsen Pharma Biotech SAS

[+2]

100 Clinical Results associated with Ipsen Pharma Biotech SAS

Login to view more data

0 Patents (Medical) associated with Ipsen Pharma Biotech SAS

Login to view more data

100 Deals associated with Ipsen Pharma Biotech SAS

Login to view more data

100 Translational Medicine associated with Ipsen Pharma Biotech SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data